| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.93 M USD | -612186 USD | 6.09 M USD | 8.45 M USD | 6.34 M USD | 5.42 M USD | 3.06 M USD | 3.11 M USD | -557714 USD | 569478 USD | 5.88 M USD | 6.69 M USD |
| Depreciation & Amortization | 4.15 M USD | 4.90 M USD | 4.94 M USD | 5.33 M USD | 4.61 M USD | 4.75 M USD | 4.40 M USD | 2.98 M USD | 2.65 M USD | 2.40 M USD | 2.25 M USD | 1.99 M USD |
| Stock-Based Compensation | 408320 USD | 301895 USD | 365040 USD | 447503 USD | 741867 USD | 1.05 M USD | 1.49 M USD | 1.36 M USD | 1.12 M USD | 852102 USD | 622503 USD | 761663 USD |
| Capital Expenditures | 97903 USD | 66461 USD | 281268 USD | 102148 USD | 103532 USD | 140817 USD | 246202 USD | 455569 USD | 275960 USD | 130872 USD | 142965 USD | 163258 USD |
| Cash Flow from Investing | -4.71 M USD | 57842 USD | -105695 USD | -13.67 M USD | -501893 USD | -1.76 M USD | 2.30 M USD | -27.72 M USD | 9.51 M USD | -3.12 M USD | -2.34 M USD | -6.03 M USD |
| Cash Flow from Financing | -6.75 M USD | 196904 USD | -7.42 M USD | -2.06 M USD | -3.55 M USD | -7.12 M USD | -5.08 M USD | 7.14 M USD | 1.95 M USD | -1.15 M USD | -5.19 M USD | -1.66 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | 263478 USD | 579049 USD | 740533 USD | 1.05 M USD | 1.39 M USD | 1.85 M USD | 3.49 M USD | 2.88 M USD | 3.72 M USD | 2.52 M USD | 5.34 M USD | 4.32 M USD |
| Free Cash Flow | 4.83 M USD | -678647 USD | 5.81 M USD | 8.35 M USD | 6.24 M USD | 5.27 M USD | 2.81 M USD | 2.66 M USD | -833674 USD | 438606 USD | 5.73 M USD | 6.53 M USD |
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative prescription products aimed at improving patient care. The company primarily operates in the healthcare sector, offering a portfolio of niche-market prescription products that address significant medical needs. Cumberland's product range includes treatments for hospital acute care settings, gastroenterology, and oncology, catering to specific therapeutic segments. Founded in 1999 and headquartered in Nashville, Tennessee, the company leverages a network of direct salesforce alongside partnerships with other health care providers and distributors to ensure broad product availability across the United States market. Cumberland Pharmaceuticals plays a critical role in the healthcare industry by providing essential medications that enhance treatment outcomes and address unmet medical needs. Its commitment to expanding therapeutic options and improving patient access to specialized treatments underscores its significance in the pharmaceutical market.